103 related articles for article (PubMed ID: 8106073)
21. Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine.
Piotrowski J; Piotrowski E; Slomiany A; Slomiany BL
J Physiol Pharmacol; 1995 Dec; 46(4):463-9. PubMed ID: 8770790
[TBL] [Abstract][Full Text] [Related]
22. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
[TBL] [Abstract][Full Text] [Related]
23. Retinoic acid differentially affects platelet-derived growth factor and epidermal growth factor-regulated cell growth of mouse osteoblast-like cells.
Tsukamoto T; Matsui T; Takaishi T; Ito M; Fukase M; Chihara K
Cell Growth Differ; 1994 Feb; 5(2):207-12. PubMed ID: 8180134
[TBL] [Abstract][Full Text] [Related]
24. Helicobacter pylori upregulates expression of epidermal growth factor-related peptides, but inhibits their proliferative effect in MKN 28 gastric mucosal cells.
Romano M; Ricci V; Di Popolo A; Sommi P; Del Vecchio Blanco C; Bruni CB; Ventura U; Cover TL; Blaser MJ; Coffey RJ; Zarrilli R
J Clin Invest; 1998 Apr; 101(8):1604-13. PubMed ID: 9541490
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine phosphorylation of EGF-R and PDGF-R proteins during acute cutaneous wound healing process in mice.
Gope ML; Gope R
Wound Repair Regen; 2009; 17(1):71-9. PubMed ID: 19152653
[TBL] [Abstract][Full Text] [Related]
26. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[TBL] [Abstract][Full Text] [Related]
27. Adaptation of gastric mucosa to stress. Effect of ranitidine.
Ernst H; Konturek PC; Brzozowski T; Lochs H; Hahn EG; Konturek SJ
J Physiol Pharmacol; 1998 Sep; 49(3):405-19. PubMed ID: 9789793
[TBL] [Abstract][Full Text] [Related]
28. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[TBL] [Abstract][Full Text] [Related]
29. Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents.
Slomiany BL; Piotrowski J; Slomiany A
J Physiol Pharmacol; 1999 Jun; 50(2):197-210. PubMed ID: 10424717
[TBL] [Abstract][Full Text] [Related]
30. Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells.
Böhmer FD; Böhmer A; Obermeier A; Ullrich A
Anal Biochem; 1995 Jul; 228(2):267-73. PubMed ID: 8572305
[TBL] [Abstract][Full Text] [Related]
31. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression.
Oda Y; Wehrmann B; Radig K; Walter H; Röse I; Neumann W; Roessner A
Gen Diagn Pathol; 1995 Oct; 141(2):97-103. PubMed ID: 8548600
[TBL] [Abstract][Full Text] [Related]
32. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[TBL] [Abstract][Full Text] [Related]
33. Spatial organization of EGF receptor transmodulation by PDGF.
Liu P; Anderson RG
Biochem Biophys Res Commun; 1999 Aug; 261(3):695-700. PubMed ID: 10441488
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
35. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M; Kwiecień N; Obtułowicz W; Konturek SJ; Kamiński K; Oleksy J; Gabryelewicz A; Torres J
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[TBL] [Abstract][Full Text] [Related]
36. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of ebrotidine.
Piotrowski J; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Jun; 27(1):131-8. PubMed ID: 1385705
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of growth factors to degradation by Helicobacter pylori protease: effect of ebrotidine and sucralfate.
Slomiany BL; Piotrowski J; Slomiany A
Biochem Mol Biol Int; 1996 Sep; 40(1):209-15. PubMed ID: 8886287
[TBL] [Abstract][Full Text] [Related]
39. Dopamine D2 receptor stimulation of mitogen-activated protein kinases mediated by cell type-dependent transactivation of receptor tyrosine kinases.
Wang C; Buck DC; Yang R; Macey TA; Neve KA
J Neurochem; 2005 May; 93(4):899-909. PubMed ID: 15857393
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
